Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 1/20 | 0.44 | |
| ▸ | FURIN | P09958 | 4/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.40 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 1/20 | 0.37 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101471 | 0.81 | PDF (0.45) | PDFFURINCA1CA2KLKB1 | |
| SCHEMBL27291531 | 0.80 | FURIN (0.49) | PDFFURINCA1CA2KLKB1 | |
| SCHEMBL24393476 | 0.77 | FURIN (0.40) | FURINMMP3 | |
| SCHEMBL20149172 | 0.77 | FURIN (0.49) | FURINGAA | |
| SCHEMBL24864663 | 0.74 | KLKB1 (0.48) | PDFCA1CA2KLKB1SSTR3 | |
| SCHEMBL27291534 | 0.74 | FURIN (0.48) | PDFFURINCA1CA2KLKB1 | |
| SCHEMBL15686242 | 0.73 | NMT2 (0.45) | PDFFURINKLKB1SSTR3PLG | |
| SCHEMBL24864484 | 0.73 | KLKB1 (0.47) | PDFCA1CA2KLKB1SSTR3 | |
| SCHEMBL24864487 | 0.73 | KLKB1 (0.44) | PDFFURINCA1CA2KLKB1 | |
| SCHEMBL24390289 | 0.73 | SIRT1 (0.45) | PDFFURINKLKB1SSTR3MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220133902-A1 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220133902-A1 | Composition Comprising a Combination of Immune Checkpoint Inhibitor and Antibody-Amatoxin Conjugate for Use in Cancer Therapy | CD47, CD274, PDCD1LG2 | PDF 1695/4885FURIN 956/4885CA1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.